Orchid Pharma Q4 FY26 Results (NSE: ORCHPHARMA)
Signal: Margin pressure
The read
Orchid Pharma delivered a Q4 that appears positive on the surface (PAT +6.8% YoY) but the quality is poor — the entire profit is manufactured from other income (167% of PBT) and an exceptional reversal of a prior provision. Full-year FY26 tells the real story: revenue -12%, PAT -79%, and a MODIFIED AUDIT OPINION on consolidated results. The company is investing heavily in subsidiary assets (CWIP tripled to ₹340 Cr) and acquired the Allecra/Enmetazobactam franchise globally, which has yet to generate meaningful revenue. Net debt ballooned from ₹109 Cr to ₹248 Cr. Until the Enmetazobactam/Exblifep commercial ramp-up delivers top-line growth, the core business remains under pressure from domestic/API competition, and investors are paying 185x earnings for a business with falling operating profits and an adverse audit opinion.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2.38 Cr | 0.4% | 15.1% |
| EBIT | ₹0.41 Cr | -62.9% | |
| Net profit | ₹0.24 Cr | 6.8% | |
| EPS | ₹4.69 | 6.6% | |
| EBIT margin | 9.4% |
P&L walk
Consolidated Q4 revenue marginally grew 0.4% YoY, but full-year revenue fell 12% — operating weakness persists. EBITDA margin compressed 470bps YoY to 9.4%, though recovered QoQ from near-zero. PAT for Q4 jumped 6.8% YoY to ₹23.78 Cr, but this was entirely propped up by other income (167% of PBT) and a ₹5.39 Cr exceptional reversal — operating EBIT fell 63%. For full year FY26, PAT collapsed 79% on a 12% revenue decline. Auditors issued a MODIFIED OPINION on consolidated results (Basis for Qualified Opinion not reproduced here — see full AR).
Segments
The company reports a single operating segment (Pharmaceuticals). The material divergence between standalone (PAT ₹45.21 Cr FY26) and consolidated (PAT ₹20.55 Cr) indicates that subsidiaries — particularly OBPL (Jammu facility), Orchid Pharma Europe, and/or the Allecra assets — are either in heavy investment phase or incurring losses, dragging group earnings.
Key positives
- Q4 revenue stabilised (+0.4% YoY) after four quarters of decline, potentially a trough
- Consolidated OCF improved sharply to ₹101.20 Cr from ₹19.22 Cr due to inventory liquidation and tax benefits
- Standalone auditor opinion is UNMODIFIED (clean), and operational cash flow positive for the year
- Company now owns 100% global rights to Enmetazobactam (Exblifep) — a differentiated novel antibiotic with USD 178M licensing potential over 10 years from regulatory approval
Key concerns
- Full-year FY26 consol revenue -12% YoY to ₹811 Cr; core pharma operations declining
- Consol PAT plunged 79.4% to ₹20.55 Cr; Q4 bottom-line is entirely dependent on other income (167% of PBT) and a one-off exceptional reversal (₹5.39 Cr)
- Consolidated EBITDA margin compressed to 9.4% (-470bps YoY); operating EBIT down 63%
- AUDITED REPORT CARRIES MODIFIED OPINION on consolidated results — severe governance / accounting concern
- Net debt surged from ₹109 Cr to ₹248 Cr as massive capex (CWIP ₹340 Cr) was debt-funded
- P/E of 185x on sharply falling earnings is unsustainable — 3-year PAT CAGR of -73%
Earnings quality: includes other income and an exceptional item
Research and educational content only. Not investment advice.